Transforming ocular surface care.
Advanced regenerative solutions designed to improve patient outcomes, increase practice efficiency, and elevate the standard of care.
A premium partner for the next era of ocular surface care.
RenVia exists to bring regenerative innovation into the hands of eye care professionals — with clinical credibility, operational simplicity, and partnership that scales with your practice.
Improve Outcomes
Deliver regenerative therapies that support healing and patient satisfaction — backed by lyophilized amniotic biology.
Increase Efficiency
Simplify storage, handling, and implementation. Ambient-temperature inventory, no rehydration, no compromise.
Grow Revenue
Expand treatment options for ocular surface disease while improving practice economics and patient retention.
What makes XcellerEYES different.
Compare lyophilized regenerative biology against legacy approaches — and see why thousands of clinicians are making the switch.
The power of lyophilization.
Six steps that transform regenerative biology into a stable, shelf-ready, clinician-friendly allograft.
Lyophilization
Sublimation removes water without disrupting biological integrity.
Vacuum-driven freeze-drying produces a dry, stable allograft — eliminating cold-chain dependencies while preserving structure.
Built for the cases that need more than drops.
XcellerEYES has been used by providers across the U.S. for a broad spectrum of ocular surface and post-surgical indications.
A case we should explore?
Talk with a RenVia clinical specialist about how XcellerEYES could fit into your treatment algorithm.
See XcellerEYES in practice.
Hands-on demonstrations, application techniques, and the science behind lyophilization — from leading clinicians.
Outcomes that earn trust.
Lyophilized amniotic membrane has been studied across multiple ocular indications. Below are representative outcomes and operational metrics from the field.
XcellerEYES has changed how we manage persistent epithelial defects. The handling is simple, and we are seeing meaningful reepithelialization.
Ambient storage removed a real operational pain point. We can stock the product without restructuring our clinic logistics.
For surgical temporary ocular discomfort, this has become a first-line tool in our refractive workflow.
* Representative practice-reported outcomes. Individual results vary. Refer to peer-reviewed literature and the XcellerEYES instructions for use for indication-specific evidence.
Real practices. Real workflows. Real results.
Persistent epithelial defect non-responsive to topical therapy after 6 weeks.
Single XcellerEYES application via direct technique with bandage contact lens.
Reepithelialization observed by week 2; patient discharged from acute treatment by week 4.
Built to help physicians access the next era of regenerative ophthalmology.
RenVia was created to help eye care professionals access innovative regenerative technologies that improve outcomes and elevate patient care. As a trusted U.S. commercialization partner for Oculus Biologics and the XcellerEYES product line, we sit at the intersection of regenerative science and clinical practice.
Ready to elevate ocular surface care?
Tell us about your practice. A RenVia clinical specialist will reach out within one business day to discuss product evaluation, ordering, and clinical support.
- Personalized product evaluation
- Clinical onboarding & training
- Dedicated commercial support
- Streamlined ordering through your existing workflow